Lilly adds liver fat, CGM blood sugar data to mountain of evidence on hot diabetes prospect tirzepatide

Eli Lilly has added to the mountain of data it is piling up in support of diabetes prospect tirzepatide. The latest additions to the pile come from two phase 3 sub-studies that linked the dual GIP/GLP-1 agonist to improvements in patients using continuous glucose monitors and reductions in liver fat.